Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00364026
NCT00364026CompletedPhase 2

A Phase II Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-201)

Gilead Sciences0 sitesStarted: June 1, 2004Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Primary Endpoint
Co-primary efficacy measures are changes in trough sitting systolic BP from baseline through Weeks 8 and 10.
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic blood pressure in subjects with resistant systolic hypertension, despite treatment with full doses of three or more blood pressure lowering drugs, including a diuretic.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
35 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subjects who are competent to provide written consent
  • •Aged 35 to 85 years
  • •Subjects with diabetes and/or chronic kidney disease must have a mean systolic blood pressure ≥130 mmHg
  • •All other subjects must have a mean systolic blood pressure ≥140 mmHg
  • •Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic
  • •Female subjects of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the time of Randomization.

Exclusion Criteria

  • •Average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg at Screening
  • •Serum ALT or AST >2X ULN
  • •Subjects who have experienced myocardial infarction, unstable angina, or a cerebrovascular accident (CVA) within 6 month of the Screening Visit; or sick sinus syndrome or second or third degree atrioventricular block, chronic atrial fibrillation or recurrent atrial tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia
  • •Implanted cardioverter defibrillator (ICD) that has fired for any arrhythmia within 3 months of Screening or implanted pacemakers
  • •Symptomatic CHF requiring treatment
  • •Hemodynamically significant valvular heart disease
  • •Hemodialysis or peritoneal dialysis; or history of renal transplant
  • •Diagnosis or recurrence of malignancy within the past 3 years
  • •Sleep apnea
  • •Subjects who perform alternating shift or night work
  • •Subjects who have participated in a clinical study involving another investigational drug or device within 1 month of the Screening Visit

Outcomes

Primary Outcomes

Co-primary efficacy measures are changes in trough sitting systolic BP from baseline through Weeks 8 and 10.

Secondary Outcomes

  • Secondary efficacy measurements are change in trough sitting diastolic BP from baseline to study Week 10; change in mean 24-hour systolic BP, as measured by ABPM; and the percent of subjects who reached systolic BP goal after 10 weeks of treatment.

Investigators

Sponsor Class
Industry

Similar Trials

Completed
Phase 3
DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant HypertensionHypertension
NCT00330369Gilead Sciences352
Terminated
Phase 3
DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant HypertensionHypertension
NCT00353574Gilead Sciences282
Completed
Phase 2
Daridorexant to Prevent Delirium After Heart SurgeryPOSTOPERATIVE DELIRIUMPOSTOPERATIVE COGNITIVE DECLINE
NCT06630390University of Rochester11
Terminated
Phase 3
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant HypertensionHypertension
NCT00389675Gilead Sciences661
Completed
Phase 2
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal CancerMetastatic Colorectal Cancer
NCT03122509Memorial Sloan Kettering Cancer Center25